Retraction note: Cervical type AB thymoma (mixed) tumour diagnosis in a mynah as a model to study human: clinicohistological, immunohistochemical and cytohistopathological study

Khaki, Fariba; Javanbakht, Javad; Sasani, Farhang; Gharagozlou, Mohammad; Bahrami, Alimohammad; Moslemzadeh, Hemmat; Sheikhzadeh, Reza

doi:10.1186/s13000-016-0567-2

Cited by 1 publication

(1 citation statement)

References 6 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The type A thymoma derives from the central medulla region of thymus and has neoplastic cells with spindle or oval shape, whereas the type B thymomas originate from thymic cortex on the periphery with the presence of immature lymphocytes (Weksler and Lu, 2014). Type AB thymoma is generally regarded to combine features from both type A and type B (Green et al, 2015;Khaki et al, 2013). The TC, often occurring in 5-10% of the TET patients (Kelly, 2013;Lamarca et al, 2013;Ried et al, 2016), consists of a variety of diverse tumors, among which thymic squamous cell carcinoma (TSCC) is the most frequently observed Moser et al, 2014;Scorsetti et al, 2016;Takahama et al, 2017;Weissferdt et al, 2012;Wu et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

Deciphering tissue‐based proteome signatures revealed novel subtyping and prognostic markers for thymic epithelial tumors

Sun

Zhu

et al. 2020

Molecular Oncology

View full text Add to dashboard Cite

Thymic epithelial tumors (TETs) belong to a group of tumors that rarely occur, but have unresolved mechanisms and heterogeneous clinical behaviors. Current care of TET patients demands biomarkers of high sensitivity and specificity for accurate histological classification and prognosis management. In this study, 134 fresh‐frozen tissue samples (84 tumor, 40 tumor adjacent, and 10 normal thymus) were recruited to generate a quantitative and systematic view of proteomic landscape of TETs. Among them, 90 samples were analyzed by data‐independent acquisition mass spectrometry (DIA‐MS) leading to discovery of novel classifying molecules among different TET subtypes. The correlation between clinical outcome and the identified molecules was probed, and the prioritized proteins of interest were further validated on the remaining samples (n = 44) via parallel reaction monitoring (PRM) as well as immunohistochemical and confocal imaging analysis. In particular, two proteins, the cellular mRNA deadenylase CCR4 (carbon catabolite repressor 4)‐NOT (negative on TATA) complex subunit 2/9 (CNOT2/9) and the serine hydroxymethyltransferase that catalyzes the reversible interconversions of serine and glycine (SHMT1), were found at dramatic low levels in the thymic epithelia of more malignant subtype, thymic squamous cell carcinoma (TSCC). Interestingly, the mRNA levels of these two genes were shown to be closely correlated with prognosis of the TET patients. These results extended the existing human tissue proteome atlas and allowed us to identify several new protein classifiers for TET subtyping. Newly identified subtyping and prognosis markers, CNOT2/9 and SHMT1, will expand current diagnostic arsenal in terms of higher specificity and prognostic insights for TET diagnosis and management.

show abstract